On November 10, the U.S. Department of Health and Human Services announced that the FDA is initiating the removal of certain black box warnings from hormone replacement therapy products for menopause,...
Secretary Robert F. Kennedy Jr. announced that the CDC will no longer recommend the COVID-19 booster vaccine for healthy children and pregnant people. The announcement comes despite previous CDC...
In June, following a placebo-controlled trial, the FDA approved pembrolizumab with chemotherapy to treat patients with primary advanced or recurrent endometrial carcinoma.
Earlier this year, the FDA approved the same vaccine for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.
The US Food and Drug Administration recently approved a new treatment option for patients with early stage HER2-overexpressed/amplified breast cancer. For recommended dosage and common adverse events, read...
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.